Singapore markets close in 12 minutes

ABBV Jun 2023 110.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
36.250.00 (0.00%)
As of 03:55PM EST. Market open.
Full screen
Loading interactive chart…
  • Zacks

    AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

    AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

  • Reuters

    Abbvie plans to lift $2 billion cap on deals - WSJ

    Chief Executive Officer Richard Gonzalez said the company now has the capacity "to do more", in an interview with WSJ that was published on Monday. Abbvie is hoping to replace the loss of revenue from Humira through its newer immunology drugs Skyrizi and Rinvoqn, and has forecast sales of over $21 billion from the two products in 2027.

  • Motley Fool

    2 Stocks Down More Than 6% to Buy Right Now

    In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.